PVR and neoplasm: The results of this study demonstrated that OAd-SIRPα-Fc, OAd-Siglec10-Fc and OAd-TIGIT-Fc were able to produce SIRPα-Fc, Siglec10-Fc and TIGIT-Fc, respectively, which effectively bound to CD47+, CD24+ and CD155+ tumor cells (Fig. 2e).